Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cigall Kadoch
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Foghorn Therapeutics
Other : member of the fiduciary Board of Directors
please see attachment
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
PROJECT NARRATIVE While immunotherapy has transformed treatment for numerous malignancies, this benefit has not been fully realized in prostate cancer. To overcome this critical challenge, we have created a multidisciplinary and highly collaborative program to define immune cell composition, states, and interactions that mediate selective immunotherapy response; prove that specific tumor-intrinsic somatic mutations in chromatin regulators drive immunotherapeutic responses in a heterogeneous prostate cancer population; and identify combination treatment strategies to boost responses in aPD-1 non-responsive PCa. Overall, this program will conduct systematic how promote and comprehensive investigations of tumor cells evade the immune system, and anti-tumor immune responses. host immune cell-prostate cancer cell interactions to define identify strategies to reprogram immune and tumor cells to
Filed on September 28, 2018.
Tell us what you know about Cigall Kadoch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Cigall Kadoch”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $200,000 - $249,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $150,000 - $199,999 |
| Cigall Kadoch | Sarc | Conflict of Interest | Dana-Farber Cancer Institute | $150,000 - $199,999 |
| Cigall Kadoch | Beth Israel Deaconess Medical Center | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.